Is SENS a Buy? What to Consider in 2026
Short answer
The bull case for Senseonics Holdings (SENS) rests on Eversense 365 one-year differentiation: Eversense 365 extends sensor life to a full year, a meaningfully different experience from the 10-to-15-day disposable patches sold by larger competitors. Full-year 2025 revenue is ~$35.3M (up from ~$22.5M in 2024). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Senseonics competes against Dexcom and Abbott, both far larger, profitable, and better capitalized, and either can press on price, reimbursement access, or product cadence. Whether SENS is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Senseonics Holdings develops and commercializes Eversense, a continuous glucose monitoring system for people with diabetes built around a small sensor implanted just under the skin of the upper arm. Unlike the disposable adhesive sensors from Dexcom and Abbott that last roughly 10 to 15 days, Eversense is designed for long-term wear, and the current Eversense 365 version is approved for up to one year on a single sensor, paired with a removable transmitter and a phone app. The long-wear, low-maintenance profile is the company's core differentiator in an otherwise patch-dominated category.
What's the case for buying SENS?
Eversense 365 one-year differentiation
Eversense 365 extends sensor life to a full year, a meaningfully different experience from the 10-to-15-day disposable patches sold by larger competitors. Fewer replacements and an implantable form factor give the product a distinct position with users who want less frequent maintenance, and management has tied recent growth in new patient starts and improving gross margin to 365 adoption.
Bringing commercialization in-house from Ascensia
Eversense was historically distributed through a partnership with Ascensia Diabetes Care. Senseonics has been transitioning commercial, sales, and distribution rights back in-house in both the U.S. and Europe. Eliminating the revenue share with Ascensia is intended to lift gross margin and give the company direct control of marketing, though it also adds operating expense as it builds that infrastructure.
A large and growing CGM market
Continuous glucose monitoring continues to expand as use spreads beyond insulin-dependent diabetes toward broader type 2 and prediabetes populations. Senseonics is also pursuing automated insulin delivery (AID) integrations and a next-generation sensor program. A small share of a large, growing category is the bull framing, but capturing it requires execution against entrenched incumbents.
Margin and revenue inflection underway
Reported revenue grew sharply in 2025 and into 2026 as Eversense 365 ramped and the Ascensia revenue share rolled off, with gross margin improving from near breakeven. Management raised full-year 2026 revenue guidance, signaling confidence in the trajectory, though the business is still operating at a substantial net loss.
What are the risks to SENS?
Senseonics competes against Dexcom and Abbott, both far larger, profitable, and better capitalized, and either can press on price, reimbursement access, or product cadence. Scale is small, so a single reimbursement decision, manufacturing issue, or slower-than-expected patient adoption can move results materially. The company remains unprofitable and burns cash, so it has relied on equity and debt financing that can dilute shareholders. Reimbursement and regulatory outcomes across the U.S. and Europe add further uncertainty.
How is SENS valued? (as of 2026-06-27)
- Full-year 2025 revenue: ~$35.3M (up from ~$22.5M in 2024)
- Q1 2026 revenue: ~$11.7M (up ~87% year over year)
- Full-year 2026 revenue guidance: ~$60M to $64M (raised; ~70-82% growth)
- Q1 2026 net loss: ~$32.3M (vs ~$14.3M a year earlier)
- Cash, equivalents and investments: ~$64.6M as of March 31, 2026 (debt ~$35.2M)
- Market capitalization: ~$280M (early June 2026)
These figures describe a speculative growth company, not a mature one: revenue is rising quickly off a small base while net losses remain large relative to sales. Cash on hand and recent financing support the Eversense 365 launch and pipeline, but continued losses mean future capital raises are possible. All figures are approximate and tied to the asOf date; verify against the latest filings before acting.
How do you decide if SENS is a buy?
Rather than asking whether SENS is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold SENS indirectly through an index or sector ETF before adding more.
For the full picture, see the SENS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about SENS against your real portfolio and see your actual exposure before deciding.
The bottom line on SENS
The bottom line: Senseonics Holdings's story right now is Eversense 365 one-year differentiation, with full-year 2025 revenue at ~$35.3M (up from ~$22.5M in 2024). If you believe that narrative continues, the call is about sizing SENS sensibly and checking overlap with what you own; if you doubt it (the risk: senseonics competes against Dexcom and Abbott, both far larger, profitable, and better capitalized, and either can press on price, reimbursement access, or product cadence.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around SENS with Walnut
Use Senseonics Holdings as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is SENS a good stock to buy right now?
+
The case for Senseonics Holdings right now is Eversense 365 one-year differentiation, with full-year 2025 revenue at ~$35.3M (up from ~$22.5M in 2024). If you believe that thesis holds, SENS is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is senseonics competes against Dexcom and Abbott, both far larger, profitable, and better capitalized, and either can press on price, reimbursement access, or product cadence. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Senseonics Holdings do?
+
Senseonics Holdings develops and commercializes Eversense, a continuous glucose monitoring system for people with diabetes built around a small sensor implanted just under the skin
What are the main risks of SENS?
+
Senseonics competes against Dexcom and Abbott, both far larger, profitable, and better capitalized, and either can press on price, reimbursement access, or product cadence. Scale is small, so a single reimbursement decision, manufacturing issue, or slower-than-expected patient adoption can move results materially. The company remains unprofitable and burns cash, so it has relied on equity and debt financing that can dilute shareholders. Reimbursement and regulatory outcomes across the U.S. and Europe add further uncertainty.
What does Senseonics do?
+
Senseonics develops and sells Eversense, a continuous glucose monitor for people with diabetes. Its differentiator is an implantable sensor placed just under the skin of the upper arm that is worn long term, with the current Eversense 365 version approved for up to one year, paired with a removable transmitter and a smartphone app.
Is SENS a good stock to buy right now?
+
That depends on your own goals and risk tolerance, and this page does not give advice. The bull case is a genuinely differentiated one-year implantable CGM in a large, growing market with rising revenue and improving margins. The bear case is heavy competition from Dexcom and Abbott, ongoing losses, small scale, and dilution risk from future financing.
Is SENS profitable?
+
No. Senseonics is not profitable. It reported a net loss of roughly $69 million for full-year 2025 and a wider loss of about $32 million in the first quarter of 2026 as it took commercialization in-house. Revenue is growing quickly off a small base, but expenses still exceed sales, which is typical of an early-stage medical-device company.
Does SENS pay a dividend?
+
No. Senseonics does not pay a dividend. It is an unprofitable, growth-stage medical-device company that reinvests its capital into commercializing Eversense 365, building its in-house sales infrastructure, and funding its product pipeline. Investors in SENS would be looking for potential share-price appreciation rather than dividend income, and that potential is speculative.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell SENS; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.